Nixon looked like a choir boy compared Bill and the current group of Dems. What hypocrites are in main stream media.
from 93 cents that he hasn't been able to cover. His vocabulary doesn't stray far from idiot, or moron. I feel sorry for you man. I know that this stupidity problem of yours affects your personality. But man up dude. You make it so obvious that your intellect is on the level of a third grader and that is more of an insult to the third grader than you. Quit embarrassing yourself.
For a guy who knows so much you don't bring anything to the table but being a critic. Your one liners are boring and you are probably such a pleasure to be around. Live alone do you?
You must use a crystal ball to trade because you aren't looking at any level II tools.
3,284,723 buys, vs 498,703 sells and 244,343 at market. approximately 15 minutes ago.
Pre-arrange Market Makers transaction on the sly thanks to shorts helping to drive the price down. Why not buy at these prices when you know it is going up soon. Fair warning.
"The fundamental pricing decisions that pharmaceutical manufacturers make when they launch new, innovative drug products, particularly those that address chronic, rarer diseases and cancer and often are biological, and then adjust those prices (usually upward) over time will be a central piece of the debate on drug prices, said Larri A. Short of Arent Fox LLP in Washington. These drugs often are priced in the thousands and sometimes hundreds of thousand of dollars a year, she said"
They continue to ignore the real reason for high drug cost which is the approval process and outdated regulations which gives the FDA far too much control and influence. There is no reason, through process manipulations, the FDA should be allowed to arbitrarily put small biotechs out of business. Typical corruption and influence giving little bureaucrats more power than they can handle, or deserve
“Recent court decisions suggest that FDA restrictions on off-label advertising may abridge the First Amendment,” Fish & Richardson's Mahn said. “The Supreme Court is likely to weigh in and, if it does, FDA rules may need to be revised or eliminated,” he said.
“I think the FDA's going to bite the bullet on off-label issues and issue guidance,” John Kamp, consulting counsel to Wiley Rein LLP in Washington and executive director of the Coalition for Healthcare Communication, an industry group that promotes the free exchange of scientific and medical information, told Bloomberg BNA.
“I think the FDA's Chief Counsel's office ‘gets' it and the staff at CDER ‘gets' it and they will do something,” Kamp added........
....Indeed, Woodcock has stated that taking a new look at drug advertising and promotion in light of current jurisprudence around the First Amendment is one of the agency's priorities for 2016..
He'll be alright, it's you I worry about. I don't know if you will be able to recover your losses with that little pee brain of yours.